Identification of C38 colon adenocarcinoma growth under bevacizumab therapy and without therapy

Model identification allows to design different control strategies for antiangiogenic cancer therapy, and create model-based treatment protocols. These model-based protocols can be more effective than the current ones, since they provide individual treatment for the patients. The aim of this paper is to investigate C38 colon adenocarcinoma growth in three different cases: (1) tumor growth without therapy, (2) tumor growth with one Avastin dose for a 18-day therapy (10 mg/kg), (3) tumor growth with one-tenth dose of control Avastin dose spread over 18 days. Parametric model identification was carried out for these three cases and the relationship between the measured tumor attributes (volume, mass and vascularization) was analyzed. Effect of low-dose therapy was also examined.